Pyrazole derivative

1. A compound represented by the following formula (I-b):

or a pharmaceutically acceptable salt thereof, or a solvate thereof,

wherein

p represents an integer of 0 to 2;

q represents an integer of 0 to 3;

Z represents N or CR 5 ;

R 1 each independently represents a halogen atom, a hydroxyl group, a nitro group, a cyano group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a halogenated C 1-6 alkyl group, a C 2-6 alkenyl group, a C 1-6 alkoxyl group, a halogenated C 1-6 alkoxyl group, a C 1-6 alkoxylcarbonyl group, a hydroxy C 1-6 alkyl group, a C 1-6 alkoxyl C 1-6 alkyl group, a C 2-7 alkanoyl group, a C 1-6 alkylthio group, a C 1-6 alkylsulfinyl group, a C 1-6 alkylsulfonyl group, an —NR 7 R 8 group, or a —CONR 7 R 8 group

wherein R 7 and R 8 in the —NR 7 R 8 group and the —CONR 7 R 8 group each independently represent a substituent selected from among a hydrogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a hydroxy C 1-6 alkyl group, a cyanated C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl group, a C 6-14 aryl group, a C 7-20 aralkyl group, a heterocyclic group, a C 2-7 alkanoyl group, a hydroxy C 2-7 alkanoyl group, a halogenated C 2-7 alkanoyl group, a C 3-8 cycloalkylcarbonyl group, a C 6-14 arylcarbonyl group, a C 7-20 aralkylcarbonyl group, a heterocyclic carbonyl group, a mono-/di-C 1-6 alkylcarbamoyl group, a mono-/di-halogenated C 1-6 alkylcarbamoyl group, a mono-/di-C 3-8 cycloalkylcarbamoyl group, a mono-/di-C 6-14 arylcarbamoyl group, a mono-/di-C 7-20 aralkylcarbamoyl group, a mono-/di-heterocyclic carbamoyl group, a C 1-6 alkylsulfonyl group, a halogenated C 1-6 alkylsulfonyl group, a C 3-8 cycloalkylsulfonyl group, a C 6-14 arylsulfonyl group, a C 7-20 aralkylsulfonyl group, a heterocyclic sulfonyl group, a mono-/di-C 1-6 alkylsulfamoyl group, a mono-/di-halogenated C 1-6 alkylsulfamoyl group, a mono-/di-C 3-8 cycloalkylsulfamoyl group, a mono-/di-C 6-14 arylsulfamoyl group, a mono-/di-C 7-20 aralkylsulfamoyl group, and a mono-/di-heterocyclic sulfamoyl group;

R 2 represents a hydrogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a hydroxy C 1-6 alkyl group, or a C 1-6 alkoxyl C 1-6 alkyl group;

R 3 each independently represents a halogen atom, a cyano group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a hydroxy C 1-6 alkyl group, a C 1-6 alkoxyl group, a halogenated C 1-6 alkoxyl group, or a C 1-6 alkoxyl C 1-6 alkyl group;

R 4 represents a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 3-8 cycloalkyl group, a hydroxy C 1-6 alkyl group, a C 1-6 alkoxyl group, a halogenated C 1-6 alkoxyl group, a C 1-6 alkoxyl C 1-6 alkyl group, a C 1-6 alkylthio group, a C 1-6 alkylsulfonyl group, a —CONR 7 R 8 group, an —NR 7 R 8 group, a C 6-14 aryl group, a 3- to 14-membered non-aromatic heterocyclic group, or a 5- to 7-membered monocyclic heteroaryl group,

wherein R 7 and R 8 in the —NR 7 R 8 group and the —CONR 7 R 8 group have the same definitions as those of R 7 and R 8 in the above R 1 , and

wherein the C 3-8 cycloalkyl group, the C 6-14 aryl group, the 3- to 14-membered non-aromatic heterocyclic group, and the 5- to 7-membered monocyclic heteroaryl group, which are represented by R 4 , are each optionally substituted with one to three groups selected from among a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a hydroxy C 1-6 alkyl group, a C 1-6 alkoxyl group, a halogenated C 1-6 alkoxyl group, a C 1-6 alkoxyl C 1-6 alkyl group, a C 1-6 alkylthio group, a C 1-6 alkylsulfonyl group, a —CONR 7 R 8 group, an —NR 7 R 8 group, a C 6-14 aryl group, a 3- to 14-membered non-aromatic heterocyclic group, and a 5- to 7-membered monocyclic heteroaryl group, wherein R 7 and R 8 in the —NR 7 R 8 group and the —CONR 7 R 8 group have the same definitions as those of R 7 and R 8 in the above R 1 ;

R 5 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxyl group, a halogenated C 1-6 alkoxyl group, or a C 1-6 alkoxyl C 1-6 alkyl group; and

ring A′ represented by the following partial structural formula (II′):

is selected from the group of the heteroaryls consisting of the following:

and R 6 represents a hydrogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, or a hydroxy C 1-6 alkyl group.

2. The compound of claim 1 wherein p represents an integer of 1 to 2; q represents an integer of 0 to 1.

3. The compound of claim 1 wherein p represents an integer of 0 to 2; q represents an integer of 0 to 1.

4. The compound of claim 1 wherein R 1 each independently represents a halogen atom, a C 1-6 alkyl group, or a halogenated C 1-6 alkyl group.

5. The compound of claim 4 wherein R 1 each independently represents chlorine, a methyl group, an ethyl group, a difluoromethyl group, or a trifluoromethyl group.

6. The compound of claim 1 wherein R 2 represents a C 1-6 alkyl group.

7. The compound of claim 1 wherein R 3 each independently represents a hydrogen atom, a halogen atom, or a cyano group.

8. The compound of claim 1 wherein R 4 represents a C 6-14 aryl group, a 3- to 14-membered non-aromatic heterocyclic group, or a 5- to 7-membered monocyclic heteroaryl group wherein the C 6-14 aryl group, the 3- to 14-membered non-aromatic heterocyclic group, and the 5- to 7-membered monocyclic heteroaryl group, which are represented by R 4 , are optionally substituted with one or two groups selected from among a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxyl group, and a C 1-6 alkoxyl C 1-6 alkyl group.

9. The compound of claim 8 wherein R 4 represents phenyl, 2-pyridinyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,5-difluorophenyl, 2-methylphenyl, 2-methoxyphenyl, pyrrolidinyl, 3-fluoropyrrolidinyl, 2-methylpyrrolidinyl, 2-trifluoromethylpyrrolidinyl, 2-methoxymethylpyrrolidinyl, or 2,6-dimethylmorpholinyl.

10. The compound of claim 1 wherein ring A′ represented by the following partial structural formula (II′):

is selected from the group of the heteroaryls consisting of the following:

and R 6 represents a hydrogen atom or a C 1-6 alkyl group.

11. A compound represented by the following formula (I-b):

or a pharmaceutically acceptable salt thereof, or a solvate thereof,

wherein

p represents an integer of 0 to 2;

q represents an integer of 0 to 1;

Z represents N or CR 5 ;

R 2 represents, a C 1-6 alkyl group;

R 3 each independently represents a hydrogen atom, a halogen atom, or a cyano group;

R 4 represents a C 6-14 aryl group, or a 3- to 14-membered non-aromatic heterocyclic group wherein the C 6-14 aryl group and the 3- to 14-membered non-aromatic heterocyclic group, which are represented by R 4 , are each optionally substituted with one or two groups selected from among a halogen atom, a C 1-6 alkyl group, and a C 1-6 alkoxyl group;

R 5 represents a hydrogen atom, or a halogen atom; and

p, R 1 , and ring A″ are combined, represents a 1-methyl-1H-imidazol-4-yl group, a 4-(difluoromethyl)-5-methylthiazol-2-yl group, a 4-(difluoromethyl)thiazol-2-yl group, a 4-(trifluoromethyl)thiazol-2-yl group, a 4-ethylthiazol-2-yl group, a 4-methylthiazol-2-yl group, or a 5-chloro-4-(difluoromethyl)thiazol-2-yl group.

12. A compound which is selected from:

N-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-4-(4-(trifluoromethyl)thiazol-2-yl)-1H-pyrazole-5-carboxamide,

4-(4-(difluoromethyl)thiazol-2-yl)-N-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide,

4-(4-(difluoromethyl)thiazol-2-yl)-1-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxamide,

4-(4-(difluoromethyl)thiazol-2-yl)-N-(2-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide,

4-(4-(difluoromethyl)thiazol-2-yl)-N-(2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide,

4-(4-ethylthiazol-2-yl)-1-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxamide,

N-(6-fluoro-2-phenyl-[1,2,4]triazolo[15-a]pyridin-7-yl)-1-methyl-4-(1-methyl-1H-imidazol-4-yl)-1H-pyrazole-5-carboxamide,

or a pharmaceutically acceptable salt thereof, or a solvate thereof, or optical isomers.

13. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 12 , a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutically acceptable carrier.